Abstract:For chronic hepatitis C virus (HCV) infection, the effects of current therapies are limited. To evaluate the efficacy and safety of the interferon beta-1a (IFN β-1a) versus IFN β-1a plus ribavirin (RBV) combination on Chinese treatment-naïve patients with chronic hepatitis C, a randomized, placebo-controlled study was performed. A total of 26 naïve patients histologically confirmed to have chronic hepatitis C were double-blindly and randomly assigned to receive either IFN β-1a 44 μg (12 MIU) (IFN β-1a group) or placebo (placebo group) three times per week for 12 weeks. At the end of the 12 weeks of treatment, the patients who received IFN β-1a continued to complete 24 weeks of treatment. Placebo non-responders were crossed over to IFN β-1a plus RBV (1,000–1,200 mg/day) combination therapy (IFN β-1a plus RBV group) for 24 weeks after 4 weeks washout. All patients were followed up for 24 weeks after the end of treatment. Sustained virological response (SVR) was defined as the absence of detectable HCV RNA in the serum both at the end of 24 weeks of treatment and at the end of 24 weeks of untreated follow-up. There were no differences in the clinical background between the groups before the initiation of treatment. At the end of the 12 weeks of double-blind therapy, HCV RNA was negative and undetectable in 10/11 patients (90.9%) in the IFN β-1a group and none in the placebo group. The virological response rate (14/15, 93.3%) of the IFN β-1a plus RBV group at week 12 after the initiation of therapy was similar to that of the IFN β-1a group. SVR was observed in 5/11 (45.5%) of the IFN β-1a group and 11/15 (73.3%) of the IFN β-1a plus RBV group (P = 0.23). At the end of follow-up, a biochemical response was found in 5/11 patients in the IFN β-1a group (45.5%) and 8/15 patients in the IFN β-1a plus RBV group (53.3%, P = 1.00). Multiple logistic regression analysis confirmed that an HCV RNA load lower than 1.0×106 copies/ml was independently associated with SVR (OR 11.00; 95% CI 1.81–66.97; P = 0.003). The side effects were mild and similar in the two therapy groups. We conclude that IFN β-1a alone or in combination with RBV provided considerable benefit in Chinese naïve patients with chronic hepatitis C. Treatments with IFN β-1a alone or IFN β-1a plus RBV are safe and well tolerated, and may represent an alternative for chronic hepatitis C patients who are unable to tolerate pegylated interferon α.

Effects of interferon and ribavirin combination therapy on microRNA122 expression in Huh7 cells

Effect Of Ribavirin And Interferon Beta On Mirna Profile In The Hepatitis C Virus Subgenomic Replicon-Bearing Huh7 Cells

Efficacy of combination sofosbuvir and pegylated interferon-α in treatment of patients with chronic hepatitis C:a Meta-analysis

[Influence of Mir-122 on IFN-α Treatment for HCV Infection].

Interferon-α and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus

miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV.

[Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].

Interferon Beta 1a Versus Interferon Beta 1a Plus Ribavirin for the Treatment of Chronic Hepatitis C in Chinese Patients: A Randomized, Placebo-Controlled Trial

An Observation on the Effectiveness of the Patient with Chronic Hepatitis C by Combining Interferon and Ribavirin

The Preliminary Efficacy of Interferon-Alpha and Ribavirin Combination Treatment of Chronic Hepatitis C in HIV-infected Patients.

MicroRNA-122 protects against interferon-α-induced hepatic inflammatory response via the Janus kinase-signal transducer and activator of transcription pathway

Changes of Inflammatory Cytokines/chemokines During Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin Therapy for Patients with Genotype 1b Hepatitis C Infection

INHIBITION OF HEPATITIS B VIRUS BY COMBINED Sirnas IN VITRO

The Effects of Hepatitis C Virus Core Protein on the Expression of Mir-122 in Vitro

[Effects of Mir-122 on Expression of Hepatitis B Virus Proteins].

Alteration of mi-RNA expression profile after interferon treatment in HCV-infected Huh7.5.1 cells]

Gene Expression Profiles in an Hepatitis B Virus Transfected Hepatoblastoma Cell Line and Differentially Regulated Gene Expression by Interferon-Alpha

Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells.

Interferon Alpha-2B with and Without Ribavirin in the Treatment of Hepatitis B E Antigen-Positive Chronic Hepatitis B: a Randomized Study.

The expression of serum microRNA-122 in patients with chronic hepatitis B virus-related liver failure and its relationship with severity of disease

Hcv Replication in Pbmc and Its Influence on Interferon Therapy